<DOC>
	<DOCNO>NCT01334827</DOCNO>
	<brief_summary>The purpose study compare , contrast , characterize range user perception potential acceptability three ( 3 ) topical vaginal microbicide dosage form .</brief_summary>
	<brief_title>A Formative Study Explore Sensory Perceptions Vaginal Product Users</brief_title>
	<detailed_description>The success microbicide product derive synergy biological functionality user acceptability . Biological functionality integrate result safe effective anti-HIV compound incorporate dosage form device successfully deliver compound target tissue , fluid , pathogen . Acceptability multi-factorial phenomenon account personal , dyadic , product-related , social context potentiate - - woman 's decision use microbicide . Acceptability ( assess , part , user ' sensory perception product use ) depend strongly upon dosage form and/or delivery system biophysical function and/or mechanical material property conducive human use . Without , microbicides ' potential decisively alter public health impact HIV/AIDS sexually transmit infection largely limited . The current protocol specifically study impact gel volume user perception , well extend user perception scale development include property product `` behavior '' experience use vaginal film .</detailed_description>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Women : age 18 45 report vaginal sex male sexual partner past 6 month report monogamous sexual relationship male partner report consistent use effective birth control method : e.g. , hormonal contraceptive , IUD , bilateral tubal ligation , Essure® nonincisional permanent birth control procedure , hysterectomy ( partial total , with/without oophorectomy ) , partner 's vasectomy/salpingectomy able tolerate film use , measure pelvic exam Visit 1B willing refrain vaginal product use ( inclusive douching ) 48 hour Visit 1B complete study activity ( except studyrelated product ) willing refrain vaginal intercourse 24 hour Visit 1B Visits 24 willing use condom vaginalpenile sex study visit ( Visits 1A 4 ) willing refrain nonpenile vaginal penetration dosage form evaluation visit ( Visits 24 ) willing undergo HIV test receive test result counsel . Men : least 18 year age report vaginal sex female sexual partner past 6 month report monogamous sexual relationship female sexual partner willing refrain vaginal intercourse 24 hour Visit 1B Visits 24 willing use condom vaginalpenile sex study visit ( Visits 1A4 ) willing refrain nonpenile vaginal penetration dosage form evaluation visit ( Visits 24 ) willing use nonlubricated latex condom ( provide ) penilevaginal intercourse dosage form evaluation visit ( Visits 24 ) willing undergo HIV test receive test result counsel . Women men ineligible : unable unwilling give inform consent partner unable unwilling give inform consent currently enrol vaginal product study/studies STI ( Neisseria gonorrhea , Chlamydia trachomatis , bacterial vaginosis , trichomoniasis , syphilis ) , HIV positive upon screen ( Visit 1A ) , pregnant ( female ) study visit breastfeeding , complete menopause ( i.e. , least 12 month without menstrual period ) ( female participant ) currently attempt get pregnant intention get pregnant participation study clinically significant abnormal pelvic finding and/or finding require therapy function clinical exam Visits 1A and/or 1B ( female participant ) report within 30 day last pregnancy outcome gynecologic surgical procedure know , suspect , allergy component study product similar ingredient product know , suspect , allergy latex condition , opinion study clinician principle investigator , would compromise participant´s ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>topical microbicide</keyword>
	<keyword>primary prevention</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>drug delivery system</keyword>
</DOC>